Cheaper and Faster than Conventional Therapies

“The average cost of antibiotic treatment over the 6-month period was 192% higher for a control group patient (£683.64) than the average for a CAP patient (£234.03).”

The annual National Health Service (NHS) cost of wound management in the UK for 2017/18 was GB£8.3 billion. Of this, £5.6 billion was spent on managing unhealed wounds (Guest et al., 2020), including diabetic foot ulcers (DFUs) (Everett and Mathioudakis,2018). In 2014-2015 costs for ulceration and amputation in people with diabetes (PWD) was estimated at between £837 million and £962 million with more than 90% of expenditures related to ulceration (Kerr et al 2019).

In the USA, about 38 million Americans have diabetes, and each year a staggering 154,000 Americans will suffer amputations, roughly 80% of which will be the result of complications from diabetes. Their life expectancy following this procedure is five years.

Our mission has always been to revolutionise the global infection market. Bringing an innovative technology which aims to disrupt the conventional infection management market by delivering a more reliable, faster, and effective means of treatment. The SteriPlas has been doing exactly that since its launch many years ago and has expanded to cover the UK, EU and SE Asia with more plans to expand into new territories bringing the benefits to others who have yet to use our medical device.

For more information about our strong clinical efficacy and Health Economics, contact us at info@adtecplasma.com